ResMed delivered a strong set of financial results in the last quarter and managed an all-around beat. With its dedicated global team and improved supply and manufacturing capabilities, ResMed has been able to meet the market demand and provide life-saving products and therapy solutions to patients worldwide. They have made significant progress in expanding the availability of their cloud-connected devices, particularly with the AirSense 10 platform in North America and other major markets. While they are still addressing some supply chain challenges with the AirSense 11 platform, they are on track to meet the global demand for connected CPAP and APAP devices by the end of 2023. ResMed’s continuous growth in both device revenue and mask/accessory business reflects their market leadership and the positive response from customers. Additionally, their investments in digital health technology and software solutions drive better patient outcomes and adherence. As they strive to improve 250 million lives through better healthcare by 2025, ResMed’s team remains committed to innovation, scaling production, and delivering comprehensive care to patients globally. We give ResMed a ‘Hold’ rating with a revised target price.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
Want unlimited access to our reports? Purchase our $99 annual subscription!